December 30, 2014

Haploidentical Donor BMT Program Launched

New hope for patients with no bone marrow donor match

Haplotypes_690x380

Blood cancers, such as leukemia, and other blood diseases, such as sickle cell anemia, are potentially curable with a blood and marrow transplant, but, until recently, only two-thirds of patients were able to find a suitably matched donor. The remaining third with no donors were not able to get the benefit of transplant.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Traditionally, an HLA-matched donor is preferred for blood and marrow transplantation. In April 2014, Cleveland Clinic launched a haploidentical donor transplantation program that now allows use of HLA-half matched (haplotype) donors. Biological parents and children and half-matched siblings can serve as donors. The ability to use haploidentical donors is of special relevance to patient populations who previously had very limited sibling and unrelated donor options, such as patients with sickle-cell disease that disproportionately afflicts African-Americans.

“This is a step toward offering a donor for every patient,” says Rabi Hanna, MD, Director, Pediatric Blood & Marrow Transplant Program, Cleveland Clinic Children’s. “Now, barring any health conditions or other issues that would prevent donation, a parent can donate and siblings may also be half matches.”

The preferred donor sources continue to be an HLA-identical sibling or HLA-matched unrelated donor. For patients without these donor options, a haploidentical donor or umbilical cord blood can be used for transplantation.

Advertisement

“We can add haploidentical donor transplantation to the list of significant advances in transplant technology and supportive care that have positively impacted patient survival and outcomes,” says Navneet Majhail, MD, MS, Director, Adult Blood & Marrow Transplant Program, Cleveland Clinic. “With a donor option now available for more or less all patients, timely referral for a transplant is key to achieving optimal patient outcomes.”

Seven procedures have been performed as of July, with a 30-day survival rate of 100 percent.

Overcoming Rejection

The concept of haploidentical transplantation is not new, but previous technologies have been thwarted by high rates of graft rejection or a potentially fatal post-transplant complication called graft-versus-host disease. To overcome these significant risks, the new approach involves administering cyclophosphamide in the immediate days following transplant to destroy alloreactive immune cells that mediate the graft-versus-host and host-versus-graft reactions while sparing hematopoietic stem cells. High rates of engraftment with acceptable risks of transplant complications and mortality have been reported with this technique.

Advertisement

Serving Children and Adults

Cleveland Clinic is among the few programs in the nation to routinely offer haploidentical donor transplantation, and serves adult and pediatric patients. Haploidentical transplantation is also available for patients who qualify for participation in a large NIH clinical trial, which is also available at Cleveland Clinic.

CNR-4000

Related Articles

Doctors working on MGUS screening study
March 18, 2024
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Physician with patient
March 6, 2024
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Doctor measuring patient's waist size
February 26, 2024
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

24-CNR-4545611-CQD-Podcast-967×544
February 1, 2024
Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

Disparities in multiple myeloma
January 25, 2024
Major Study Identifies Global Disparities in Drug Toxicity for Multiple Myeloma Treatment

Study of 401,576 patients reveals differences in cancer burdens as well as overall survival

Dr. Shilpa Gupta
December 27, 2023
A New Standard Emerges in Advanced Urothelial Carcinoma After Decades of First-Line Chemotherapy

Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy

Ad